JNJ 10-Q Quarterly Reports

Johnson & Johnson (JNJ) reported robust financial results for the fiscal third quarter ending September 27, 2025. Sales increased by 6.8% year-over-year to $24.0 billion, driven by strong performance in both the Innovative Medicine and MedTech segments. Net earnings saw a significant jump to $5.2 billion, translating to diluted earnings per share of $2.12, compared to $2.7 billion and $1.11 in the prior year's third quarter. This performance reflects broad-based growth across key therapeutic areas and product lines, alongside effective cost management. The company demonstrated strong operational execution, with a positive impact from currency fluctuations and strategic acquisitions contributing to top-line growth. The balance sheet remains solid, with total assets growing to $192.8 billion. The company's strategic focus on innovation and portfolio management is evident in the performance of its Innovative Medicine segment, which saw sales rise by 6.8% driven by strong oncology and neuroscience offerings, notably bolstered by the recent acquisition of CAPLYTA. The MedTech segment also performed well, with sales increasing by 6.8%, supported by growth in Cardiovascular and Vision franchises, including contributions from the Shockwave acquisition. Despite ongoing legal matters, particularly related to talc and opioids, the company's financial strength and operational efficiency continue to drive shareholder value.

Johnson & Johnson (JNJ) reported a strong second quarter for fiscal year 2025, demonstrating robust sales growth and improved profitability. Worldwide sales increased by 5.8% to $23.7 billion, driven by solid performance across both the Innovative Medicine and MedTech segments. The Innovative Medicine segment saw a notable 4.9% increase in sales, propelled by strong oncology product performance, particularly from CARVYKTI and DARZALEX, alongside the recent acquisition of Intra-Cellular Therapies contributing to the neuroscience portfolio. The MedTech segment also delivered a healthy 7.3% sales increase, benefiting from the integration of Shockwave Medical and continued strength in cardiovascular and surgical solutions. Net earnings significantly rose to $5.5 billion, or $2.29 per diluted share, compared to $4.7 billion, or $1.93 per diluted share, in the prior year's quarter. This increase was significantly aided by the reversal of a substantial portion of the previously accrued talc reserve, which contributed positively to the 'Other (income) expense, net' line item. The company maintained its commitment to shareholders through dividend payments and share repurchases, underscoring a positive financial outlook.

Johnson & Johnson (JNJ) reported a strong first quarter for fiscal year 2025, with worldwide sales reaching $21.9 billion, a 2.4% increase year-over-year. This growth was driven by a robust operational increase of 4.2%, partially offset by a 1.8% negative currency impact. The Innovative Medicine segment showed resilience with a 2.3% sales increase, fueled by strong performance in Oncology, particularly with products like Darzalex and CARVYKTI, despite a significant 33.7% decline in Stelara sales due to biosimilar competition. The MedTech segment also grew by 2.5%, boosted by the recent acquisition of Shockwave Medical and continued strength in Cardiovascular and Vision product lines. The company reported a substantial increase in net earnings to $11.0 billion from $3.3 billion in the prior year's quarter. This significant jump was largely influenced by the reversal of approximately $7.0 billion related to the previously accrued talc reserve, which had a material positive impact on the 'Other (income) expense, net' line item. Excluding this one-time item, operational performance remains solid, demonstrating the company's ongoing ability to drive growth across its diverse portfolio.

Johnson & Johnson reported a total sales increase of 5.2% to $22.5 billion for the fiscal third quarter of 2024, with operational growth of 6.3%, partially offset by a negative currency impact. For the nine-month period, total sales grew by 4.0% to $66.3 billion, with operational growth of 5.6%. The company's Innovative Medicine segment showed resilient growth, with sales increasing by 4.9% in the third quarter and 3.9% for the nine-month period, driven by strong performance in Oncology and Pulmonary Hypertension, despite headwinds in Immunology and Infectious Diseases. The MedTech segment also demonstrated positive momentum, with sales up 5.8% for the quarter and 4.1% for the nine months, boosted by the acquisition of Shockwave Medical and strong performance in Electrophysiology and Cardiovascular areas. However, the company's earnings before provision for taxes saw a significant decrease in the third quarter to $3.3 billion from $5.2 billion in the prior year, primarily impacted by substantial charges related to talc matters ($2.0 billion in the quarter). The nine-month period showed an increase in earnings before taxes to $12.8 billion from $10.2 billion, driven by higher sales and a reduction in talc-related charges compared to the prior year's nine-month period. J&J continues to manage significant legal matters, particularly concerning talc and opioid litigation, which have led to substantial accruals and charges impacting profitability. The company's balance sheet remains robust, with cash and cash equivalents of $20.0 billion, and it continues to return capital to shareholders through dividends and share repurchases.

Johnson & Johnson reported solid performance for the second quarter of 2024, demonstrating revenue growth driven by strong performance in its Innovative Medicine and MedTech segments. Total sales increased by 4.3% year-over-year to $22.4 billion, with operational growth of 6.6%, partially offset by currency headwinds. The Innovative Medicine segment saw a 5.5% increase in sales, propelled by robust growth in Oncology and Pulmonary Hypertension, despite a decline in COVID-19 vaccine revenue and ongoing biosimilar competition for certain products. The MedTech segment also delivered growth, up 2.2%, boosted by acquisitions and strong performance in Cardiovascular and Orthopaedics. Financially, the company maintained healthy profitability, although earnings before taxes saw a slight decrease due to significant charges related to acquisitions and ongoing litigation settlements, particularly concerning talc matters. The company continues to navigate substantial legal proceedings, notably the talc and opioid litigations, which have resulted in significant accruals. Despite these challenges, Johnson & Johnson's liquidity remains strong, with substantial cash and cash equivalents, and effective management of its debt obligations. The company's strategic acquisitions, including Shockwave Medical, are expected to contribute to future growth, showcasing a continued focus on expanding its portfolio in key areas.

Johnson & Johnson reported a strong first quarter for fiscal year 2024, with total sales reaching $21.4 billion, a 2.3% increase year-over-year, driven by robust operational growth of 3.9%. The company returned to profitability with net earnings of $3.3 billion, a significant improvement from a net loss of $68 million in the prior year's first quarter. This rebound was largely influenced by a substantial reduction in legal charges, particularly related to talc matters, which decreased from $6.9 billion to $2.7 billion year-over-year. The Innovative Medicine segment showed resilience with a 1.1% sales increase, supported by strong performance in Oncology and Pulmonary Hypertension, while the MedTech segment saw a 4.5% sales boost, led by growth in Cardiovascular and Orthopaedics. Despite some headwinds, including a decline in COVID-19 vaccine revenue and ongoing biosimilar competition for key products, Johnson & Johnson demonstrated effective operational management and strategic execution. The company also continued its commitment to shareholder returns by declaring a quarterly dividend and actively repurchasing shares. The pending acquisition of Shockwave Medical, a significant move within the MedTech segment, signals a continued focus on strategic growth and portfolio enhancement.

Johnson & Johnson (JNJ) reported a mixed financial performance for the fiscal third quarter and nine months ended September 30, 2023. Total sales increased by 6.8% to $21.35 billion for the quarter and 6.2% to $63.76 billion for the nine months, driven by strong operational growth in both the Innovative Medicine and MedTech segments, as well as favorable currency impacts in the quarter. Despite the top-line growth, the company faced significant headwinds, including a substantial charge related to the talc settlement proposal which significantly impacted year-to-date earnings. The company also completed the significant separation of its Consumer Health business (Kenvue), which resulted in a large one-time gain from discontinued operations. The Innovative Medicine segment showed resilience with sales up 5.1% for the quarter and 4.2% year-to-date, with notable growth in immunology, oncology, and neuroscience products. The MedTech segment also demonstrated robust growth, up 10.0% for the quarter and 10.0% year-to-date, significantly boosted by the acquisition of Abiomed and strong performance in interventional solutions. However, the company's net earnings were heavily influenced by the large gain from discontinued operations related to the Kenvue separation, making direct comparison of profitability challenging without considering this non-recurring item.

Johnson & Johnson reported strong financial results for the second quarter of 2023, with worldwide sales increasing by 6.3% to $25.5 billion. This growth was driven by robust operational performance across all segments, particularly in MedTech and Pharmaceutical, which saw increases of 14.7% and 3.8% operationally, respectively. The company's net earnings rose to $5.14 billion, or $1.96 per diluted share, up from $4.81 billion, or $1.80 per diluted share, in the prior year's quarter. This performance demonstrates J&J's continued ability to navigate a complex global economic environment, supported by strategic pricing, innovation, and effective cost management. The company also made significant progress in its strategic separation of the Consumer Health business, Kenvue, through its successful IPO, positioning J&J to focus on its core healthcare businesses. The six-month period also showed positive momentum, with sales growing 6.0% to $50.3 billion and net earnings of $5.08 billion. While the six-month earnings were impacted by a significant charge related to the talc settlement proposal, the underlying operational performance remains strong. The company's diversified business segments, strong product pipeline, and strategic initiatives like the Kenvue separation are key drivers for future growth and shareholder value.

Johnson & Johnson (JNJ) reported a net loss of $68 million ($0.03 per share) for the first quarter of 2023, a significant shift from the $5.15 billion net earnings ($1.93 per share) in the prior year. This was primarily driven by a substantial charge of $6.9 billion related to the talc settlement proposal, which significantly impacted the "Other (income) expense, net" line item. Despite the net loss, the company's operational performance remained robust. Worldwide sales grew by 5.6% to $24.7 billion, with operational growth of 9.0% driven by strong performances across all segments: Consumer Health (7.4%), Pharmaceutical (4.2%), and MedTech (7.3%). The MedTech segment saw a notable boost from the acquisition of Abiomed. The company also maintained a strong liquidity position with $26.9 billion in cash, cash equivalents, and restricted cash.

Johnson & Johnson reported solid results for the fiscal third quarter ended October 2, 2022, with total sales reaching $23.8 billion, a 1.9% increase year-over-year, driven by operational growth that offset currency headwinds. Net earnings for the quarter were $4.5 billion, or $1.68 per diluted share. The Pharmaceutical segment demonstrated strength with a 2.6% sales increase, particularly in Oncology and Immunology, despite headwinds from biosimilar competition for REMICADE and the upcoming patent expiry for STELARA. The MedTech segment also saw a 2.1% sales increase, recovering well from the prior year. Despite a challenging macroeconomic environment marked by inflation and currency fluctuations, the company maintained a strong financial position. Cash flow from operations remained robust at $15.8 billion for the nine months ended October 2, 2022. The company also reiterated its commitment to returning capital to shareholders through dividends and share repurchases, demonstrating confidence in its ongoing performance and future outlook. The planned separation of the Consumer Health business remains on track.

Johnson & Johnson reported strong revenue growth for the second quarter of 2022, driven by operational increases across its Pharmaceutical and MedTech segments, despite a negative impact from currency fluctuations. Total sales reached $24.0 billion, a 3.0% increase year-over-year, with international sales showing particular strength due to operational growth, even as currency headwinds persisted. Net earnings for the quarter were $4.8 billion, or $1.80 per diluted share, a decrease from the prior year primarily due to an intangible asset impairment charge related to the bermekimab drug development and increased litigation-related expenses. The company continues to navigate a challenging macroeconomic environment, including inflation and supply chain pressures, while also advancing its strategic plan to separate its Consumer Health business.

Johnson & Johnson reported solid revenue growth in the first quarter of 2022, driven by strong performance in its Pharmaceutical and MedTech segments, which more than offset a slight decline in Consumer Health sales. Total sales increased by 5.0% to $23.4 billion, with operational growth contributing significantly, despite a negative currency impact. The company demonstrated robust operational sales growth across its key segments, with Pharmaceuticals up 9.3% and MedTech up 8.5%. While the company's net earnings saw a decrease compared to the prior year's first quarter, this was largely attributed to significant non-recurring items, including an intangible asset impairment charge and changes in the fair value of securities. Excluding these factors, the underlying operational performance remains strong. The company also highlighted its ongoing commitment to shareholder returns through dividends and share repurchases, and provided an update on its strategic plan to separate the Consumer Health business, expected to be completed within 18-24 months.

Johnson & Johnson (JNJ) reported strong financial results for the third quarter and first nine months of fiscal year 2021. Sales increased across all segments, driven by robust performance in the Pharmaceutical and Medical Device divisions, with notable growth in key therapeutic areas like Oncology and Immunology, as well as strong recovery in Medical Device procedural volumes. While the company experienced a net loss in the Consumer Health segment due to significant litigation expenses, particularly related to talc, the overall financial health remains robust. The company generated substantial operating cash flow, allowing for continued investment in research and development, dividend payments, and share repurchases. JNJ also demonstrated effective management of its debt, with a net debt position improving from the previous year. The company remains focused on navigating ongoing litigation and regulatory environments while pursuing strategic growth initiatives across its diverse business units.

Johnson & Johnson reported strong financial performance for the second quarter and first six months of fiscal year 2021, demonstrating significant growth across its key segments. Total sales saw a substantial increase, driven by robust operational performance and favorable currency impacts. The Pharmaceutical segment, in particular, showed remarkable growth, fueled by key products like STELARA® and DARZALEX®, alongside the emerging contribution of its COVID-19 vaccine. The Medical Devices segment also experienced a strong rebound, reflecting a recovery in global procedural volumes post-COVID-19. The company maintained a healthy cash flow from operations, which, combined with its existing credit facilities and access to capital markets, ensures strong liquidity. JNJ's strategic focus on innovation and portfolio management continues to drive top-line growth, while the company navigates ongoing litigation and regulatory landscapes. Investors can find reassurance in the consistent dividend payouts and the company's ability to generate substantial earnings despite various global economic challenges.

Johnson & Johnson (JNJ) reported strong performance for the first quarter of 2021, with total sales reaching $22.3 billion, a 7.9% increase year-over-year. This growth was driven by a 5.5% operational increase and a favorable currency impact of 2.4%. The Pharmaceutical segment was a key driver, showing a 9.6% increase in sales to $12.2 billion, fueled by strong performance in Oncology, Immunology, and Pulmonary Hypertension therapeutic areas. The Medical Devices segment also demonstrated robust growth, with sales up 10.9% to $6.6 billion, largely due to recovery in surgical procedures and strong performance in Interventional Solutions. While the Consumer Health segment experienced a slight decline of 2.3% in sales to $3.5 billion, this was attributed to comparisons with prior year COVID-19 related pantry loading and a weaker cough, cold, and flu season. Net earnings for the quarter were $6.2 billion, or $2.32 per diluted share, up from $5.8 billion, or $2.17 per diluted share, in the prior year. The company maintained a healthy cash flow from operations of $4.1 billion, supporting dividend payments and share repurchases, while also managing significant legal and restructuring reserves.

Johnson & Johnson reported a solid third quarter of 2020, with worldwide sales increasing by 1.7% to $21.1 billion. This growth was driven by operational performance across its diverse segments, particularly in the Pharmaceutical and Consumer Health divisions. The company also demonstrated effective cost management, leading to a significant increase in earnings before taxes, especially in the Pharmaceutical segment which saw a substantial rebound. Despite ongoing global economic uncertainties and the impact of COVID-19, which notably affected the Medical Devices segment, JNJ maintained a strong liquidity position with cash and cash equivalents totaling $19.0 billion. The company continued its commitment to shareholder returns through regular cash dividends and strategic investments in its pipeline, including the acquisition of Momenta Pharmaceuticals, Inc. post-quarter. While facing some headwinds, JNJ's diversified portfolio and robust financial management position it to navigate the challenging environment.

Johnson & Johnson reported second quarter 2020 results with total sales of $18.3 billion, a decrease of 10.8% year-over-year, impacted by an operational decline of 9.0% and a negative currency impact of 1.8%. The decrease was largely driven by a significant slowdown in the Medical Devices segment, which saw a 33.9% drop in sales, primarily attributed to the ongoing COVID-19 pandemic's impact on elective procedures and non-essential medical services. The Pharmaceutical segment demonstrated resilience, with sales increasing by 2.1% operationally, driven by strong performance in Oncology and Immunology, despite some headwinds from COVID-19. Net earnings for the quarter were $3.6 billion, down from $5.6 billion in the prior year's second quarter, resulting in diluted earnings per share of $1.36, a decrease from $2.08. The company's balance sheet remains strong, with total assets of $158.4 billion and total shareholders' equity of $63.0 billion as of June 28, 2020. Despite the challenging top-line performance in certain segments, Johnson & Johnson continued to return capital to shareholders through dividends and share repurchases.

Johnson & Johnson reported a 3.3% increase in worldwide sales to $20.7 billion for the fiscal first quarter ended March 29, 2020, compared to the prior year. This growth was primarily driven by operational increases, though partially offset by currency fluctuations and the initial impact of COVID-19. The Pharmaceutical segment showed strong growth, up 8.7%, led by key products like Stelara and Imbruvica. The Consumer Health segment also saw a significant 9.2% increase, largely due to elevated demand for OTC products, likely influenced by the pandemic. However, the Medical Devices segment experienced an 8.2% decline, attributed to the postponement of elective procedures due to COVID-19 and the divestiture of the Advanced Sterilization Products business. Net earnings surged to $5.8 billion, a substantial increase from $3.7 billion in the prior year, leading to a diluted EPS of $2.17, up from $1.39. A significant factor contributing to the increased profitability was a $1.0 billion contingent consideration reversal related to the Auris Health acquisition. The company maintained a strong liquidity position with $15.5 billion in cash and cash equivalents, despite using cash for dividends and stock repurchases. While the company acknowledges the uncertainties posed by COVID-19, it currently does not foresee a material impact on its financial position, attributing this resilience to its diversified business model and robust business continuity plans.

Johnson & Johnson (JNJ) reported net earnings of $1.753 billion for the third quarter of 2019, down significantly from $3.934 billion in the same period of 2018. This decline was largely driven by a significant "Other (income) expense, net" of $4.214 billion in the current quarter, primarily attributed to an "agreement in principle to settle opioid litigation." For the nine months ended September 29, 2019, net earnings were $11.109 billion, compared to $12.255 billion in the prior year. Despite the earnings dip, worldwide sales for the third quarter of 2019 increased by 1.9% to $20.7 billion, with operational growth of 3.2%, driven by strong performance in the Pharmaceutical segment, particularly in Oncology and Immunology. The Medical Devices segment saw a slight operational decline, impacted by divestitures. Investors should note the significant legal and restructuring charges impacting profitability, while recognizing the underlying operational sales growth and continued strength in key pharmaceutical product lines.

Johnson & Johnson (JNJ) reported second-quarter 2019 results with total sales of $20.6 billion, a slight decrease of 1.3% year-over-year, impacted by operational growth of 1.6% and a currency headwind of 2.9%. Net earnings for the quarter were $5.6 billion, a significant increase from $4.0 billion in the prior year's second quarter, leading to diluted earnings per share of $2.08, up from $1.45. The substantial increase in net earnings was notably influenced by a large gain of $2.0 billion from the divestiture of the Advanced Sterilization Products (ASP) business and an equity step-up gain of $0.3 billion from the Dr. Ci: Labo investment. Operationally, the Pharmaceutical segment showed resilience with 4.4% growth, driven by strong performance in Immunology and Oncology, although REMICADE® and ZYTIGA® faced pressures from biosimilar and generic competition, respectively. The Medical Devices segment experienced an operational decline of 4.1%, significantly impacted by divestitures of LifeScan and ASP, while the Consumer segment saw modest operational growth of 4.6%, boosted by acquisitions and strong performance in Beauty and OTC products. The company's liquidity remains strong, with $14.4 billion in cash and cash equivalents. Financing activities included substantial dividends paid and share repurchases. JNJ continues to navigate ongoing litigation and regulatory matters, with particular attention to product liability claims and patent challenges, though management does not expect these to have a material adverse effect on the company's financial position.

Johnson & Johnson (JNJ) reported revenues of $20.02 billion for the first quarter of 2019, a slight increase of 0.1% year-over-year, with operational growth of 3.9% offset by a negative currency impact of 3.8%. Net earnings decreased to $3.75 billion, or $1.39 per diluted share, compared to $4.37 billion, or $1.60 per diluted share, in the prior year's first quarter. This decrease was largely driven by significant one-time charges, including a $0.9 billion in-process research and development (IPR&D) impairment charge related to the AL-8176 development program and a $0.3 billion litigation expense. The Pharmaceutical segment showed strong operational growth of 7.9%, driven by key products like Stelara and Tremfya, while the Consumer segment experienced a slight sales decline of 2.4%. The Medical Devices segment also saw a decrease in sales of 4.6% overall. Despite the net earnings decline, the company generated substantial operating cash flow and continues its commitment to returning capital to shareholders through dividends and share repurchases.

Johnson & Johnson reported solid performance for the nine months ended September 30, 2018, with worldwide sales increasing by 8.8% to $61.2 billion, driven by strong operational growth and a positive currency impact. Net earnings for the nine months were $12.3 billion. The company's diverse segments, including Pharmaceutical and Medical Devices, demonstrated robust growth, with key products like STELARA®, IMBRUVICA®, and vision care products showing significant gains. The company also made strategic acquisitions and divestitures, including the acquisition of Actelion and the divestiture of its LifeScan business, aimed at optimizing its portfolio and driving future growth. In the third quarter, worldwide sales grew by 3.6% to $20.3 billion, with Pharmaceutical and Medical Device segments showing continued strength. The company maintained its commitment to returning value to shareholders through dividends and share repurchases. Despite facing ongoing litigation and regulatory scrutiny, particularly concerning talc-based powders and certain pharmaceutical products, Johnson & Johnson reiterated its expectation that these matters will not have a material adverse effect on its financial position, though they may impact results of operations in specific periods.

Johnson & Johnson reported a strong second quarter for fiscal year 2018, with worldwide sales reaching $20.83 billion, an increase of 10.6% year-over-year. This growth was driven by robust operational performance and a positive impact from currency fluctuations. The Pharmaceutical segment was a significant contributor, showcasing impressive operational growth, particularly in Oncology and Immunology, fueled by strong demand for key products like Stelara and Darzalex. The company's net earnings for the quarter rose to $3.95 billion, translating to diluted earnings per share of $1.45, up from $1.40 in the prior year's second quarter. Cash flow from operations remained strong, providing ample liquidity for investments in growth and shareholder returns. The company also announced strategic initiatives, including pending divestitures of its LifeScan and Advanced Sterilization Products businesses, and the acquisition of Zarbee’s, Inc., signaling a continued focus on portfolio optimization.

Johnson & Johnson (JNJ) reported a strong first quarter for 2018, with total sales reaching $20.0 billion, a 12.6% increase year-over-year. This growth was driven by robust operational performance across its segments, particularly in Pharmaceutical and Medical Devices, alongside a positive currency impact. Net earnings for the quarter were $4.37 billion, or $1.60 per diluted share, showing resilience despite increased investments and some segment-specific headwinds. The company highlighted significant growth in its Pharmaceutical segment, largely fueled by strong performance in Oncology and Pulmonary Hypertension (a new therapeutic area from the Actelion acquisition), with notable contributions from drugs like Darzalex, Imbruvica, and Zytiga. The Medical Devices segment also showed healthy growth, with Vision Care and Interventional Solutions being standout performers. While the Consumer segment saw modest growth, it faced competitive pressures and divestitures. Management's Discussion and Analysis indicates a strategic focus on innovation and growth, evidenced by continued investment in R&D and the positive impact of recent acquisitions. The company also provided an update on its ongoing restructuring initiatives aimed at optimizing operations and driving long-term efficiency. Despite ongoing litigation and regulatory environments, JNJ's financial position appears solid, with strong cash flow from operations.

Johnson & Johnson (JNJ) reported its third-quarter and nine-month results for fiscal year 2017, showcasing robust sales growth driven significantly by strategic acquisitions, most notably Actelion Ltd. The company's consolidated sales increased by 10.3% year-over-year for the third quarter and 4.6% for the nine-month period, with operational growth contributing substantially alongside positive currency impacts and the net effect of acquisitions and divestitures. Pharmaceutical segment performance was a key driver, with a notable 15.4% increase in third-quarter sales, bolstered by strong contributions from Oncology and Pulmonary Hypertension (following the Actelion acquisition). The Medical Devices segment also demonstrated healthy growth, up 7.1% in the third quarter, primarily due to the inclusion of Abbott Medical Optics (AMO) and growth in Vision Care. While the Consumer segment saw modest growth, the company continues to navigate competitive pressures in certain sub-segments. Financially, JNJ maintained a strong operating cash flow of $15.0 billion for the nine months ended October 1, 2017. However, investing activities showed a significant outflow of $14.4 billion, largely due to the substantial Actelion acquisition. Financing activities utilized $4.1 billion, primarily for dividends and share repurchases, though the previously announced $10 billion share repurchase program was completed in July 2017. The company's balance sheet reflects increased debt and intangible assets/goodwill stemming from recent acquisitions, indicating a strategic focus on expanding its pharmaceutical and medical device portfolios. Investors should note the ongoing legal proceedings and patent litigations across various product lines, which, while currently not expected to have a material adverse effect on the company's financial position, could impact future results.

Johnson & Johnson (JNJ) reported its second-quarter fiscal 2017 results, demonstrating a modest increase in worldwide sales of 1.9% to $18.8 billion. This growth was primarily driven by operational improvements across its segments, partially offset by currency fluctuations. The company's strategic acquisitions, notably Actelion, are beginning to impact the financial statements, significantly increasing intangible assets and goodwill. While overall sales showed a slight uptick, net earnings saw a decrease to $3.8 billion from $4.0 billion in the prior year's second quarter, leading to a diluted EPS of $1.40. This was influenced by higher amortization costs related to recent acquisitions, an asset impairment charge, and a gain from royalty receivable monetization. The company continues to manage its diverse portfolio, with the Pharmaceutical segment showing resilience despite biosimilar pressures on REMICADE®, and the Medical Devices segment experiencing strong growth fueled by the AMO acquisition. Investors should note the substantial investment in acquisitions and ongoing restructuring efforts as key factors influencing profitability and future growth.

Johnson & Johnson reported total sales of $17.77 billion for the first quarter of 2017, a 1.6% increase year-over-year. This growth was driven by operational expansion of 2.0%, slightly offset by currency fluctuations. The company saw a modest increase in net earnings to $4.42 billion, or $1.61 per diluted share, compared to $4.46 billion, or $1.59 per diluted share, in the prior year's first quarter. The Medical Devices segment showed the strongest growth at 3.0%, while the Pharmaceutical segment grew 0.8% and Consumer segment grew 1.0%. The company completed the acquisition of Abbott Medical Optics (AMO) for $4.4 billion, significantly increasing intangible assets and goodwill, and announced a definitive agreement to acquire Actelion Ltd. for approximately $30 billion.

Johnson & Johnson reported solid financial results for the fiscal third quarter and the first nine months of 2016. Worldwide sales increased by 4.2% to $17.8 billion for the quarter and by 2.9% to $53.8 billion for the nine-month period, driven by strong operational growth across its segments. Net earnings for the third quarter rose to $4.3 billion, or $1.53 per diluted share, compared to $3.4 billion, or $1.20 per diluted share, in the prior year. For the nine-month period, net earnings were $12.7 billion, or $4.55 per diluted share, up from $12.2 billion, or $4.33 per diluted share, in the same period of 2015. The company demonstrated robust performance in its Pharmaceutical segment, particularly in Immunology and Oncology, while the Medical Devices segment showed modest growth. The Consumer segment experienced a slight decline in sales, partly due to divestitures and operational challenges in Venezuela. Operationally, the company experienced growth driven by strategic acquisitions and strong performance in key therapeutic areas within Pharmaceuticals. Selling, marketing, and administrative expenses were managed effectively, decreasing as a percentage of sales. The company also continued its share repurchase program and declared regular quarterly dividends, reflecting its commitment to returning value to shareholders. Significant investments in research and development underscore the company's focus on future innovation across its diverse business units.

Johnson & Johnson reported solid overall sales growth for the second quarter and first six months of fiscal year 2016, driven primarily by its Pharmaceutical segment. Worldwide sales increased by 3.9% in the second quarter and 2.3% for the year-to-date period compared to the prior year, with operational growth offsetting negative currency impacts. The Pharmaceutical segment showed robust performance, with sales up 8.9% for the quarter, bolstered by strong immunology and oncology product sales, though it faced headwinds from Hepatitis C products and the impending biosimilar competition for REMICADE® in the US. The Consumer segment experienced a slight decline in sales, while the Medical Devices segment saw modest growth. Profitability was impacted by several factors, including a significant increase in litigation expenses in the Medical Devices segment and restructuring charges. Net earnings for the second quarter decreased by 11.5% to $3,997 million, or $1.43 per diluted share, compared to $4,516 million, or $1.61 per diluted share, in the prior year. For the six-month period, net earnings decreased by 4.3% to $8,454 million, or $3.02 per diluted share, down from $8,836 million, or $3.13 per diluted share, in the prior year. Despite the earnings decline, the company continued to return capital to shareholders through dividends and share repurchases, demonstrating a commitment to shareholder value.

Johnson & Johnson reported first-quarter 2016 sales of $17.5 billion, a slight increase of 0.6% year-over-year, driven by operational growth of 3.9% which was partially offset by a 3.3% negative currency impact. Net earnings for the quarter were $4.3 billion, resulting in diluted earnings per share of $1.54, a modest increase from $1.53 in the prior year's comparable period. The Pharmaceutical segment demonstrated strong performance with a 5.9% sales increase, notably driven by the Immunology and Oncology therapeutic areas. The Medical Devices segment experienced a slight sales decrease of 2.4%, while the Consumer segment saw a 5.8% decline in sales, impacted by divestitures and operational challenges. The company's balance sheet remains robust with total assets of $136.2 billion and total shareholders' equity of $72.6 billion. Cash flow from operations was $1.8 billion. Johnson & Johnson continued its commitment to returning capital to shareholders through dividends and share repurchases, paying out $2.1 billion in dividends and repurchasing $2.4 billion in stock during the quarter. The company also provided an update on ongoing litigation, with management confident that the ultimate outcome of legal proceedings, net of accrued liabilities, will not materially adversely affect the company's financial position, though it could impact results of operations and cash flows in any given period.

Johnson & Johnson reported a decline in sales for both the third quarter and the nine-month period ended September 27, 2015, compared to the prior year. This decrease was largely driven by unfavorable currency fluctuations and competitive pressures in the pharmaceutical segment, particularly affecting Hepatitis C products. Despite the revenue decline, the company demonstrated operational growth in certain segments and geographies, indicating underlying business resilience. The company also continued its commitment to returning capital to shareholders through dividends and share repurchases, highlighting financial discipline amidst a challenging macroeconomic environment.

Johnson & Johnson reported its second-quarter 2015 results, showing a decrease in worldwide sales to $17.79 billion, down 8.8% from the prior year, primarily due to negative currency impacts and the divestiture of the Ortho-Clinical Diagnostics business. Operationally, sales declined by 0.9%, with significant impacts from competitive products in the Hepatitis C market. Despite the sales decline, net earnings increased to $4.52 billion from $4.33 billion in the prior year's second quarter, resulting in diluted earnings per share of $1.61, up from $1.51. The company generated strong operating cash flow of $8.07 billion for the first six months of the year. Significant gains on asset sales, including the divestiture of NUCYNTA® license rights, positively impacted "Other Income (Expense), net" and boosted pre-tax profit in the Pharmaceutical segment. However, the Medical Devices segment saw a significant sales decline, largely due to the divestiture of the Ortho-Clinical Diagnostics business and continued pricing pressures.

Johnson & Johnson (JNJ) reported first-quarter 2015 results showing a 4.1% decrease in worldwide sales to $17.4 billion, primarily driven by unfavorable currency fluctuations (7.2% negative impact) and the impact of competitive products in its Hepatitis C offerings. Despite the sales decline, the company demonstrated resilience with operational growth in key segments. The Pharmaceutical segment saw a 10.2% operational increase, supported by strong performance in Immunology and Oncology, though tempered by competitive pressures in Hepatitis C and the impact of REMICADE® biosimilars. The Consumer segment also posted operational growth, driven by OTC and Skin Care products. The Medical Devices segment experienced an operational decline, partly due to the divestiture of the Ortho-Clinical Diagnostics business. Net earnings for the quarter were $4.3 billion, or $1.53 per diluted share, compared to $4.7 billion, or $1.64 per diluted share, in the prior year. The company continued to return capital to shareholders through dividends and share repurchases, signaling confidence in its financial health and future prospects.

Johnson & Johnson reported a significant increase in net earnings for the third quarter and the first nine months of 2014 compared to the prior year. This growth was primarily driven by strong sales performance in the Pharmaceutical segment, particularly from the hepatitis C products OLYSIO®/SOVRIAD® and INCIVO®, along with positive contributions from STELARA® and ZYTIGA®. The company also completed the divestiture of its Ortho-Clinical Diagnostics business, which contributed to a substantial net gain. While the Medical Devices and Diagnostics segment saw a decrease in sales due to this divestiture, operational improvements were noted in other areas. Management highlighted cost containment efforts and a favorable sales mix of higher-margin products as key drivers of profitability. The company also maintained a strong liquidity position, supported by robust operating cash flows and an available credit facility.

Johnson & Johnson reported strong performance for the second quarter and first six months of 2014, with worldwide sales increasing by 9.1% and 6.3% respectively compared to the prior year periods. This growth was driven by significant operational improvements, particularly in the Pharmaceutical segment, which saw sales jump 21.1% in the quarter and 16.1% year-to-date, boosted by new product launches like OLYSIO®/SOVRIAD® and strong performance from existing blockbusters like ZYTIGA® and XARELTO®. The company also demonstrated improved profitability, with earnings before taxes increasing by 17.4% for the quarter and 22.0% year-to-date. This was supported by disciplined cost management, including reduced selling, marketing, and administrative expenses as a percentage of sales, and a lower effective tax rate benefiting from a tax benefit related to the Conor Medsystems divestiture. Despite challenges in the Medical Devices and Diagnostics segment, which experienced modest growth, the overall financial health of the company appears robust.

Johnson & Johnson reported a solid first quarter for 2014, with worldwide sales reaching $18.1 billion, a 3.5% increase year-over-year. This growth was primarily driven by a robust performance in the Pharmaceutical segment, which saw a 10.8% total sales increase, fueled by strong performances in immunology, infectious diseases, and oncology. The Medical Devices and Diagnostics segment remained flat year-over-year, while the Consumer segment experienced a slight decline. Net earnings for the quarter were $4.7 billion, resulting in diluted EPS of $1.64, a notable increase from the prior year's $1.22. The company generated strong operating cash flow of $3.9 billion, despite significant uses of cash for investing activities, primarily in marketable securities, and financing activities, including dividends and share repurchases. The company also announced plans to divest its Ortho-Clinical Diagnostics business, a significant move that will reshape its business portfolio. Despite ongoing legal challenges, particularly in product liability, Johnson & Johnson maintains a confident outlook, stating that the ultimate outcome of these proceedings is not expected to have a material adverse effect on its financial position.

Johnson & Johnson reported solid financial results for the fiscal third quarter and the first nine months of 2013, demonstrating revenue growth across key segments. Total sales for the nine months ended September 29, 2013, increased by 6.6% to $53.0 billion, driven by operational growth of 8.1%, partially offset by a negative currency impact. The Pharmaceutical segment showed particularly strong performance, with sales up 10.6% for the nine months, bolstered by significant growth in Immunology and Oncology. The Medical Devices and Diagnostics segment also saw an increase of 5.7%, albeit with some segment-level declines. Net earnings for the nine months attributable to Johnson & Johnson rose to $10.3 billion, a substantial increase from $8.3 billion in the prior year period. The company also maintained a strong liquidity position, with cash and cash equivalents at $17.2 billion, and continued to return value to shareholders through consistent dividend payments.

Johnson & Johnson reported strong results for the second quarter and first six months of 2013, with worldwide sales increasing by 8.5% year-over-year to $17.9 billion for the quarter and $35.4 billion for the six-month period. This growth was driven by robust operational increases across all business segments, particularly in Pharmaceuticals and Medical Devices & Diagnostics. Net earnings for the second quarter significantly increased to $3.83 billion, or $1.33 per diluted share, compared to $1.41 billion, or $0.50 per diluted share, in the prior year period, reflecting improved profitability and a favorable equity investment transaction. The company demonstrated healthy cash flow from operations, amounting to $7.3 billion for the six-month period, supporting its investments in growth initiatives and returning capital to shareholders through dividends. Despite ongoing litigation and regulatory matters, management expressed confidence that the ultimate resolution of these issues will not materially adversely affect the company's financial position.

Johnson & Johnson reported strong top-line growth in its first quarter of 2013, with worldwide sales increasing by 8.5% to $17.5 billion. This growth was primarily driven by the Medical Devices and Diagnostics segment, which saw a significant 10.2% increase in sales, largely due to the acquisition of Synthes, Inc. The Pharmaceutical segment also demonstrated robust growth, with sales up 10.4%, propelled by strong performance in Immunology and Oncology. Despite the healthy sales figures, net earnings decreased by 10.6% to $3.5 billion, or $1.22 per diluted share, compared to $3.9 billion, or $1.41 per diluted share, in the prior year. This decline was attributed to higher litigation expenses, acquisition-related costs for Synthes, and a charge related to the devaluation of the Venezuelan currency. The company's effective tax rate also decreased significantly to 17.9% from 22.5% due to the retroactive U.S. Research & Development tax credit.

Johnson & Johnson reported strong performance in the third quarter of fiscal year 2012, with worldwide sales increasing by 6.5% to $17.1 billion compared to the prior year period. This growth was driven by significant operational improvements across all segments, particularly in Medical Devices and Diagnostics (up 12.5%) and Pharmaceuticals (up 7.0%). The company also saw a robust increase in U.S. sales across segments. Net earnings attributable to Johnson & Johnson for the quarter were $2.97 billion, a decrease from the prior year's $3.20 billion, primarily due to an $700 million in-process research and development charge related to the discontinuation of bapineuzumab IV. Despite this charge, the company demonstrated solid operational execution and strategic progress. The nine-month period ending September 30, 2012, showed worldwide sales of $49.7 billion, a 1.8% increase. Net earnings attributable to Johnson & Johnson for this period were $8.29 billion, a decrease from $9.45 billion in the prior year, also impacted by significant charges including $1.1 billion for in-process R&D and intangible asset write-downs. The acquisition of Synthes, Inc. for $20.2 billion in cash and stock, completed in the second quarter, is a significant strategic move expected to bolster the Medical Devices and Diagnostics segment. Management remains focused on cost containment and strategic investments despite ongoing litigation and regulatory scrutiny.

Johnson & Johnson (JNJ) reported its second-quarter results for fiscal year 2012, showing a decrease in net earnings to $1.4 billion from $2.8 billion in the prior year quarter, translating to diluted EPS of $0.50 compared to $1.00. This decline was significantly impacted by a large intangible asset write-down and in-process R&D charge of $1.4 billion, primarily related to the Crucell vaccine business, as well as increased litigation expenses and acquisition costs for the Synthes acquisition. Despite the net earnings decrease, the company maintained strong operational sales growth across its segments, with Medical Devices and Diagnostics showing robust performance driven by the Synthes acquisition. The Pharmaceutical segment saw growth in Immunology and Oncology, while Consumer segment sales faced challenges, partly due to ongoing issues with McNEIL-PPC manufacturing facilities. The company generated $7.5 billion in cash from operations, though investing activities, dominated by the Synthes acquisition, resulted in a net cash outflow.

Johnson & Johnson reported modest top-line performance for the first quarter of 2012, with total sales remaining relatively flat year-over-year at $16.1 billion, a slight decrease of 0.2%. This was driven by operational growth of 1.0%, which was offset by a negative currency impact of 1.2%. The company demonstrated improved profitability, with net earnings increasing to $3.91 billion from $3.48 billion in the prior year's first quarter. Diluted earnings per share also saw a healthy increase to $1.41 from $1.25. The company's diverse business segments showed varied performance. While the Pharmaceutical segment experienced robust operational growth, particularly in Immunology, the Consumer segment saw a slight decline, partly impacted by ongoing remediation efforts related to manufacturing facilities. The Medical Devices and Diagnostics segment remained largely stable. Cash flow from operations was strong, reflecting solid earnings and efficient management of working capital, enabling continued investment in operations and return of capital to shareholders through dividends.

Johnson & Johnson (JNJ) reported its third-quarter and nine-month results for the period ending October 2, 2011. For the nine months, worldwide sales increased by 6.2% to $48.8 billion, driven by a 13.2% increase in international sales which benefited from a 7.4% positive currency impact. U.S. sales, however, saw a slight decrease of 1.3%. The company's net earnings for the nine months were $9.45 billion, a decrease from $11.39 billion in the prior year, reflecting increased restructuring expenses and litigation costs. The third quarter showed continued sales growth, with worldwide sales up 6.8% to $16.0 billion, again supported by strong international performance and favorable currency movements. While overall net earnings decreased to $3.2 billion from $3.4 billion year-over-year, the company maintained robust operating cash flow of $10.8 billion for the nine-month period. Significant investments were made in acquisitions and marketable securities during the period.

Johnson & Johnson reported solid top-line growth in its Q2 2011 filing, with worldwide sales increasing by 8.3% to $16.6 billion year-over-year, driven by strong performance in international markets and a favorable currency impact. The Pharmaceutical segment was a key contributor, showing a 12.2% sales increase, bolstered by REMICADE® and international growth. The Medical Devices and Diagnostics segment also saw growth, though impacted by the discontinuation of certain coronary stent products and the lingering effects of the DePuy ASR™ Hip recall. However, the Consumer segment experienced a sales decline, partly due to manufacturing issues at its McNeil Consumer Healthcare division and an operational decline in OTC Pharmaceuticals and Nutritionals. Net earnings saw a decrease compared to the prior year, influenced by increased restructuring charges and litigation expenses, particularly in the Medical Devices and Diagnostics segment, and the impact of U.S. healthcare reform. Despite a dip in net earnings, the company maintained a strong financial position with significant cash and cash equivalents. Johnson & Johnson continued its commitment to shareholder returns by declaring an increased quarterly cash dividend. The company also announced a significant acquisition agreement for Synthes, Inc., signaling continued strategic growth initiatives, alongside ongoing efforts to manage legal challenges and operational improvements, especially within the Consumer segment.

Johnson & Johnson's (JNJ) Q1 2011 filing shows a 3.5% increase in worldwide sales to $16.2 billion, driven by international growth and a positive currency impact, despite a slight decline in U.S. sales. The company's Pharmaceutical segment demonstrated robust performance with a 7.5% sales increase, while Medical Devices and Diagnostics saw a 3.3% rise. However, the Consumer segment experienced a 2.2% sales decrease, largely due to production issues and quality enhancement efforts at McNeil Consumer Healthcare facilities. Net earnings for the quarter were $3.5 billion, or $1.25 per diluted share, a decrease from the prior year's $4.5 billion, impacted by a significant litigation gain in Q1 2010 and increased litigation expenses in the current quarter. Despite the decline in net earnings, the company generated strong operating cash flow of $2.3 billion. JNJ also continued its commitment to shareholder returns by declaring a quarterly cash dividend increase, marking the 49th consecutive year of dividend growth. The company remains focused on managing its extensive legal landscape, with ongoing proceedings across various segments, and is implementing remediation plans for manufacturing facilities. The acquisition of Crucell NV for $2 billion was a notable investment during the quarter.

Johnson & Johnson (JNJ) reported solid financial results for the fiscal third quarter ending October 3, 2010. Total sales remained relatively flat year-over-year at $14.98 billion, with a slight decrease of 0.7%, impacted by currency fluctuations. However, operational growth was positive, indicating underlying business strength. Net earnings saw a modest increase to $3.42 billion, up from $3.35 billion in the prior year's comparable quarter, resulting in diluted earnings per share of $1.23, an increase from $1.20. The company's diverse business segments showed varied performance. The Pharmaceutical segment reported a 4.7% sales increase, driven by strong performance in REMICADE® and other key drugs. The Medical Devices and Diagnostics segment also experienced growth, with a 1.3% increase in sales, supported by DePuy and Ethicon franchises. Conversely, the Consumer segment saw a notable 10.6% sales decline, primarily due to recalls and manufacturing issues impacting its Over-the-Counter (OTC) products, although proactive measures are being taken to address these challenges.

Johnson & Johnson reported solid performance for the period ending July 4, 2010, with total sales reaching $30.96 billion for the first six months, a 2.3% increase year-over-year. This growth was primarily driven by international markets, which saw a 9.0% increase in sales, partially offset by a 3.9% decline in U.S. sales. The company's pharmaceutical segment demonstrated resilience, with a 1.0% increase in sales for the quarter and a slight decrease for the six-month period, supported by strong performance in key products like REMICADE® and RISPERDAL® CONSTA®. The Medical Devices & Diagnostics segment was a significant growth driver, posting an 8.2% increase in sales for the six months, fueled by strong performance in DePuy, Ethicon Endo-Surgery, and Ethicon. However, the Consumer segment experienced a 2.0% sales decline for the six-month period, impacted by product recalls and a suspension of production at a key facility. Net earnings for the quarter were $3.45 billion, or $1.23 per diluted share, showing an improvement from the prior year's quarter. The company also continued its commitment to shareholder returns, increasing its cash dividend.

Johnson & Johnson's (JNJ) 10-Q filing for the first quarter of fiscal year 2010, ending April 3, 2010, reveals a company navigating a period of stable performance with ongoing strategic management. The report details the company's financial position, results of operations, and cash flows, providing investors with insight into the operational health of this diversified healthcare giant. Key areas of focus for investors would include the revenue generation across its various segments and the company's ability to manage its costs and cash generation effectively.

Johnson & Johnson reported solid financial results for the nine months ended September 27, 2009, despite a slight year-over-year decrease in sales of 6.6% to $45.3 billion. This decline was primarily attributed to a significant negative currency impact of 6.7% and operational challenges in certain segments, particularly Pharmaceuticals. Net earnings remained strong at $10.1 billion, demonstrating the company's resilience. The company's balance sheet shows a healthy increase in total assets to $91.6 billion from $84.9 billion in the prior year, driven by growth in intangible assets and goodwill, reflecting strategic acquisitions. Cash flow from operations was robust at $11.3 billion, underscoring the company's ability to generate substantial cash to fund operations, dividends, and strategic investments. Key strategic moves during the period included significant acquisitions such as Mentor Corporation and Cougar Biotechnology, Inc., aimed at strengthening its product portfolio and market position, particularly in the medical devices and pharmaceutical sectors. The company also continues to manage significant legal and patent litigations, with ongoing developments in several high-profile cases related to its pharmaceutical and medical device products. Despite these challenges, Johnson & Johnson maintained its commitment to returning value to shareholders, evidenced by consistent dividend payments and a focus on operational efficiency and cost containment.

Johnson & Johnson (JNJ) reported its financial results for the quarter ended June 28, 2009, and the first six months of the year. Overall sales for the six months decreased by 7.3% to $30.3 billion, impacted by a 6.0% negative currency translation effect. The company saw a decrease in sales across all major segments: Consumer (down 6.6%), Pharmaceutical (down 11.7%), and Medical Devices & Diagnostics (down 3.0%), with the Pharmaceutical segment experiencing the most significant decline, largely due to patent expirations and generic competition for key products like Risperdal and Topamax. Despite the sales decline, the company demonstrated resilience in its balance sheet, with total assets increasing to $87.4 billion from $84.9 billion at the end of 2008. Net earnings for the six months were $6.7 billion, a slight decrease from $6.9 billion in the prior year. Diluted EPS for the six months was $2.41, down from $2.43 in the same period last year. The company continued its commitment to shareholder returns by declaring an increased cash dividend, reflecting its stable operational cash flow generation.